Have a feature idea you'd love to see implemented?
Let us know!
MRSN Mersana Therapeutics Inc
Price (delayed)
$1.62
Market cap
$200.12M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.6
Enterprise value
$152.76M
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives
Highlights
Mersana Therapeutics's EPS has soared by 66% YoY and by 30% from the previous quarter
Mersana Therapeutics's net income has surged by 62% YoY and by 29% QoQ
The gross profit has grown by 16% from the previous quarter but it has contracted by 15% YoY
Mersana Therapeutics's revenue has increased by 16% from the previous quarter but it has decreased by 15% YoY
The equity has plunged by 98% YoY and by 88% from the previous quarter
MRSN's quick ratio is down by 35% year-on-year and by 13% since the previous quarter
Key stats
What are the main financial stats of MRSN
Market
Valuations
Earnings
Shares outstanding
123.53M
Market cap
$200.12M
Enterprise value
$152.76M
Price to earnings (P/E)
N/A
Price to book (P/B)
189.45
Price to sales (P/S)
5.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.39
Revenue
$34.84M
Gross profit
$34.84M
Net income
-$74.62M
EBIT
-$70.18M
EBITDA
-$63.43M
Free cash flow
-$95.57M
Per share
Balance sheet
Liquidity
EPS
-$0.6
EPS diluted
-$0.6
Free cash flow per share
-$0.78
Book value per share
$0.01
Revenue per share
$0.28
TBVPS
$1.38
Total assets
$169.53M
Total liabilities
$168.48M
Debt
$31.51M
Equity
$1.05M
Working capital
$92.26M
Debt to equity
30.03
Current ratio
2.35
Quick ratio
2.29
Net debt/EBITDA
0.75
Margins
Efficiency
Dividend
EBITDA margin
-182.1%
Gross margin
100%
Net margin
-214.2%
Operating margin
-229.5%
Return on assets
-38.6%
Return on equity
-401.4%
Return on invested capital
-104.6%
Return on capital employed
-69.3%
Return on sales
-201.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MRSN stock price
How has the Mersana Therapeutics stock price performed over time
Intraday
5.88%
1 week
-20.2%
1 month
-20.59%
1 year
-19.8%
YTD
-30.17%
QTD
-14.29%
Financial performance
How have Mersana Therapeutics's revenue and profit performed over time
Revenue
$34.84M
Gross profit
$34.84M
Operating income
-$79.95M
Net income
-$74.62M
Gross margin
100%
Net margin
-214.2%
Mersana Therapeutics's net income has surged by 62% YoY and by 29% QoQ
The operating income has soared by 61% YoY and by 29% from the previous quarter
The net margin has soared by 56% YoY and by 39% from the previous quarter
The operating margin has surged by 54% year-on-year and by 39% since the previous quarter
Growth
What is Mersana Therapeutics's growth rate over time
Valuation
What is Mersana Therapeutics stock price valuation
P/E
N/A
P/B
189.45
P/S
5.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.39
Mersana Therapeutics's EPS has soared by 66% YoY and by 30% from the previous quarter
The stock's P/B is 173% more than its last 4 quarters average of 69.3
The equity has plunged by 98% YoY and by 88% from the previous quarter
The stock's P/S is 100% below its 5-year quarterly average of 2667.1 and 37% below its last 4 quarters average of 9.1
Mersana Therapeutics's revenue has increased by 16% from the previous quarter but it has decreased by 15% YoY
Efficiency
How efficient is Mersana Therapeutics business performance
Mersana Therapeutics's ROS has soared by 57% YoY and by 40% from the previous quarter
MRSN's return on equity has dropped by 52% year-on-year and by 20% since the previous quarter
The ROA is up by 41% year-on-year and by 20% since the previous quarter
The ROIC has grown by 38% YoY and by 33% from the previous quarter
Dividends
What is MRSN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MRSN.
Financial health
How did Mersana Therapeutics financials performed over time
Mersana Therapeutics's current ratio has decreased by 36% YoY and by 14% QoQ
The company's total assets fell by 36% YoY and by 5% QoQ
The equity has plunged by 98% YoY and by 88% from the previous quarter
The debt has contracted by 8% YoY and by 2.5% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.